Stroke thrombolysis - Is more better?
- PMID: 35727070
- DOI: 10.1111/ane.13630
Stroke thrombolysis - Is more better?
Keywords: ethics; ischemic stroke; patient benefit; thrombolysis.
References
REFERENCES
-
- Bergh E, Holt Jahr S, Rønning OM, Askim T, Thommessen B, Saxhaug KE. Reasons and predictors of non-thrombolysis in patients with acute ischemic stroke admitted within 4.5 hours. Acta Neurol Scand. 2022. doi:10.1111/ane.13622
-
- Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352-2363.
-
- Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-2372.
-
- Altman DG. Practical Statistics for Medical Research. Vol 165-175. Chapman & Hall; 1991:477-500.
-
- Appelros P, Svensson E, Heidenreich K, Svantesson M. Ethical issues in stroke thrombolysis revisited. Acta Neurol Scand. 2021;144(6):611-615.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
